Endocrine

Hypoglycemia: workup and management in diabetics and nondiabetics

Clinical Overview and When to Suspect Hypoglycemia

— Level 1: glucose <70 mg/dL (alert value, action threshold)

— Level 2: glucose <54 mg/dL (clinically significant, neuroglycopenia risk)

— Level 3: severe — altered mental status or physical impairment requiring external assistance, regardless of number

— Symptoms consistent with hypoglycemia

— Low plasma glucose measured at time of symptoms

— Resolution of symptoms after glucose is raised

— Diabetic on insulin or sulfonylurea with sweating, tremor, confusion, seizure, or coma

— Any altered mental status — always check fingerstick before assuming stroke, sepsis, or intoxication

— Postprandial palpitations, diaphoresis, or syncope (reactive or post-bariatric)

— Fasting neuroglycopenia (confusion, vision change, behavior change) in nondiabetic — raises concern for insulinoma, factitious, adrenal insufficiency

— ICU patients, postoperative patients on insulin drips, sepsis, hepatic failure, malnutrition

— Adrenergic (glucose ~55–70): tremor, palpitations, diaphoresis, hunger, anxiety — driven by epinephrine

— Neuroglycopenic (<50): confusion, slurred speech, focal deficits, seizure, coma — CNS substrate deprivation

Definition (ADA, 2023):

Whipple triad (required to diagnose hypoglycemia in a nondiabetic patient):

When to suspect:

Symptom physiology:

Hypoglycemia unawareness: loss of adrenergic warning signs from recurrent hypoglycemia, autonomic neuropathy, or β-blocker use — most common in long-standing T1DM

Step 3 management: for any hospitalized patient with new altered mental status, fingerstick glucose is the first order — treat empirically with D50 IV (or glucagon IM if no IV) before extensive workup if symptomatic and low.

Board pearl: in a nondiabetic, document Whipple triad before ordering insulin/C-peptide — random labs without symptomatic hypoglycemia are uninterpretable and a classic exam trap.

Presentation Patterns and Key History

— Insulin regimen (basal, prandial, mixed), sulfonylurea (glyburide > glipizide for hypoglycemia risk), meglitinides

— Recent dose changes, new renal impairment (insulin and sulfonylurea clearance fall)

— Missed meals, alcohol intake, exercise pattern, weight loss

— Recurrent episodes, hypoglycemia unawareness, nocturnal symptoms (morning headache, vivid dreams, damp sheets)

— CGM data or logbook review

— Postprandial (reactive) hypoglycemia: 1–4 h after meals — post-gastric bypass (Roux-en-Y), idiopathic, early T2DM, noninsulinoma pancreatogenous hypoglycemia

— Fasting hypoglycemia: overnight or with skipped meals — insulinoma, adrenal insufficiency, hypopituitarism, sepsis, hepatic/renal failure, malnutrition, large non-islet tumors (IGF-2)

— Surreptitious or accidental sulfonylurea/insulin (factitious — healthcare workers, family members with diabetes)

— Quinolones (especially gatifloxacin, levofloxacin), pentamidine, quinine, indomethacin, IGF-1, β-blockers (mask symptoms)

— Alcohol binge with poor intake → impaired gluconeogenesis (classic boards stem: malnourished alcoholic, found unresponsive)

— Access to insulin or oral hypoglycemics in the home

Diabetic patient — targeted history:

Nondiabetic — ask about timing relative to food:

Medication review (critical):

Substance and social history:

Comorbid disease screen: cirrhosis, CKD/ESRD, CHF, sepsis, malignancy (mesenchymal tumors → big IGF-2), eating disorder, prior bariatric surgery

Key distinction: postprandial hypoglycemia in a healthy young adult is usually benign/reactive; fasting hypoglycemia is pathologic until proven otherwise and mandates workup.

Step 3 management: in a hospitalized diabetic with recurrent hypoglycemia, the highest-yield intervention is reviewing the medication list and renal function — hold long-acting sulfonylureas in CKD (eGFR <30) and reduce basal insulin by 10–20% before adding glucose tablets to the MAR.

Physical Exam Findings (and Hemodynamic Assessment)

— Adrenergic signs: tachycardia, hypertension, tremor, diaphoresis, pallor, mydriasis

— Neuroglycopenic signs: confusion, dysarthria, ataxia, focal deficits mimicking stroke, seizure, coma

— Hypothermia in prolonged or severe cases

— Usually tachycardic and hypertensive early; bradycardia and hypotension are late, ominous (impending arrest)

— In β-blocked patients, expect blunted tachycardia — diaphoresis may be the only autonomic clue

— Hyperpigmentation, orthostasis, hypotension: primary adrenal insufficiency

— Pallor, hair/skin changes, amenorrhea: hypopituitarism

— Bariatric surgical scars (Roux-en-Y) → postprandial pattern

— Hepatomegaly, jaundice, ascites: hepatic failure

— Cachexia, abdominal/retroperitoneal mass: IGF-2–secreting mesenchymal tumor

— Injection sites, lipohypertrophy: insulin user (clue in factitious cases)

— Goiter, vitiligo: autoimmune polyglandular syndrome (T1DM + adrenal)

— Hypoglycemia can mimic acute stroke with focal deficits — always fingerstick before code stroke imaging

— Postictal state after hypoglycemic seizure can persist after glucose correction

— Infants: jitteriness, poor feeding, hypotonia, apnea

— Elderly: falls, behavioral change, "sundowning" — often missed

Acute hypoglycemia exam:

Hemodynamics:

Focused exam for underlying cause:

Neurologic exam pitfalls:

Pediatric/elderly nuance:

CCS pearl: in the simulated case, after fingerstick confirms hypoglycemia, order continuous cardiac monitoring, IV access, repeat fingerstick q15 min, and document a focused neuro exam pre- and post-treatment. Reassess mental status at 15 minutes — failure to recover after glucose correction suggests prolonged neuroglycopenia, sulfonylurea overdose, or alternate diagnosis (stroke, postictal, intoxication).

Board pearl: focal neurologic deficits that resolve completely with D50 are pathognomonic for hypoglycemic hemiparesis — a stroke mimic.

Diagnostic Workup — Initial Labs

— Fingerstick (POC) glucose — first and fastest

— Send simultaneous venous plasma glucose to confirm (POC can be off by 10–20% at low values)

— Cause is usually obvious; no extensive workup needed

— Check BMP (renal function, electrolytes), HbA1c, review meds, dietary intake, exercise

— Trend glucose q15–30 min until stable >100 mg/dL for 2 readings

— Plasma glucose

— Insulin

— C-peptide (endogenous insulin secretion marker)

— Proinsulin

— β-hydroxybutyrate (suppressed by insulin)

— Sulfonylurea/meglitinide screen (urine or serum)

— Insulin antibodies (autoimmune insulin syndrome)

— Cortisol, ACTH (adrenal insufficiency screen)

— ↑Insulin, ↑C-peptide, ↑proinsulin, ↓β-OHB, negative sulfonylurea screen → insulinoma

— ↑Insulin, ↑C-peptide, ↑proinsulin, ↓β-OHB, positive sulfonylurea screen → sulfonylurea ingestion (accidental, factitious, malicious)

— ↑Insulin, ↓C-peptide, ↓proinsulin, ↓β-OHB → exogenous insulin (factitious or therapeutic)

— ↓Insulin, ↓C-peptide, ↑β-OHB → non-insulin mediated: alcohol, starvation, hypopituitarism, adrenal insufficiency, severe illness

— ↓Insulin, ↓C-peptide, ↓β-OHB, ↑IGF-2:IGF-1 ratio → non-islet cell tumor (IGF-2)

Immediate bedside:

If diabetic on known hypoglycemic agent:

If nondiabetic or unexplained — draw the "hypoglycemia panel" while glucose is LOW and patient is symptomatic (Whipple triad):

Interpretation framework (during documented hypoglycemia, glucose <55):

Adjuncts: BMP, LFTs, TSH, CBC, lactate, ammonia (hepatic failure), cortisol stimulation if AI suspected

Board pearl: C-peptide is the linchpin — high C-peptide means endogenous insulin (insulinoma or sulfonylurea); low C-peptide with high insulin means injected insulin. Always order them together, at the moment of hypoglycemia.

Key distinction: β-hydroxybutyrate distinguishes insulin-mediated (suppressed) from non-insulin-mediated (elevated) causes when the insulin assay is equivocal.

Diagnostic Workup — Advanced or Confirmatory Studies

— Inpatient, monitored; only water/calorie-free fluids

— Check glucose, insulin, C-peptide, proinsulin, β-OHB q6h, then q1–2h when glucose <60

— End fast when: glucose <55 with symptoms (Whipple triad met), glucose <45 regardless, or 72 h elapsed

— At termination: draw full panel, give 1 mg glucagon IV, measure glucose response (rise >25 mg/dL suggests insulinoma — hepatic glycogen preserved by hyperinsulinism)

— Multiphase pancreatic CT or MRI first-line

— Endoscopic ultrasound (EUS) highly sensitive for small (<1 cm) lesions

— 68Ga-DOTATATE PET/CT or selective arterial calcium stimulation with hepatic venous sampling for occult lesions

— Insulinomas: usually small (<2 cm), solitary, benign (90%), evenly distributed in pancreas; 5–10% associated with MEN1 → screen for hyperparathyroidism, pituitary tumors

— Cosyntropin (250 mcg) stimulation test — cortisol <18 mcg/dL at 60 min confirms AI

— ACTH level distinguishes primary vs secondary

— Large mesenchymal/epithelial tumor + ↑IGF-2:IGF-1 ratio (>10)

— CT chest/abdomen/pelvis

72-hour supervised fast (gold standard for unexplained fasting hypoglycemia):

Mixed-meal test (5 h): for postprandial hypoglycemia evaluation — preferred over OGTT (OGTT has high false-positive rate and is not recommended by Endocrine Society)

Imaging — once biochemistry localizes to insulinoma:

Adrenal insufficiency workup:

Hypopituitarism: anterior pituitary panel (TSH, free T4, LH/FSH, prolactin, IGF-1, ACTH/cortisol), pituitary MRI

Non-islet cell tumor hypoglycemia (NICTH):

Step 3 management: an inpatient supervised fast is safer and more diagnostic than an outpatient workup — admit for the 72-h fast if Whipple triad is documented and insulinoma is in the differential.

Board pearl: a normal fast (no hypoglycemia at 72 h with normal labs) rules out insulinoma with very high negative predictive value.

Risk Stratification and First-Line Management Logic

— Conscious, able to swallow, glucose <70: oral carbs — 15-15 rule (15 g fast carbs, recheck in 15 min; repeat ×3 if still low, then escalate)

— 15 g options: 4 oz juice/regular soda, 3–4 glucose tablets, 1 tbsp honey, hard candies

— Follow with a complex-carb + protein snack once >70 to prevent recurrence

— IV access available: D50W 25 g (1 amp = 50 mL) IV push, or D10W 100–200 mL infusion (gentler, preferred in fluid-restricted/pediatric)

— No IV access: glucagon 1 mg IM/SC or 3 mg intranasal (Baqsimi) — works only if hepatic glycogen present (fails in alcoholics, malnourished, prolonged fast, liver failure)

— After bolus: start D5W or D10W infusion if recurrence risk (sulfonylurea, long-acting insulin, hepatic/renal failure)

— Sulfonylurea ingestion (glyburide t½ long, especially with CKD) — admit for ≥24 h monitoring

— Long-acting insulin (glargine, degludec, NPH overdose)

— Hepatic or renal failure

— Sepsis, adrenal insufficiency

— Suicidal ingestion or factitious

— Hypoglycemia unawareness with severe episode

— Inability to eat or social isolation

— Reversible cause identified (missed meal, exercise)

— Sustained euglycemia (≥4 h post-treatment, eating normally)

— Reliable caregiver, glucometer, glucagon kit at home

— Follow-up arranged

Triage at presentation:

Altered mental status or unable to swallow:

Identify high-risk for recurrence — admit:

Discharge criteria (uncomplicated diabetic hypoglycemia):

CCS pearl: in the simulated case, after D50 push, order D10W infusion at 75–100 mL/h if the cause is sulfonylurea or long-acting insulin — single boluses are insufficient and rebound hypoglycemia is the most common reason for return visits.

Board pearl: octreotide 50–100 mcg SC q6–12h is the specific antidote for sulfonylurea-induced refractory hypoglycemia — it suppresses pancreatic insulin release. Add it early; don't keep chasing with D50.

Pharmacotherapy — Acute and Maintenance

— Dextrose: D50W 25 g IV (adults), D25W in children, D10W in neonates/infants

— Glucagon: 1 mg IM/SC (adult), 0.5 mg if <25 kg; intranasal 3 mg (Baqsimi) — useful for caregivers; expect nausea/vomiting; ineffective in glycogen-depleted states

— Octreotide: 50–100 mcg SC q6–8h for sulfonylurea toxicity; consider IV infusion in severe cases

— Hydrocortisone 100 mg IV if adrenal insufficiency suspected (give empirically with cosyntropin test pending)

— Diazoxide 3–8 mg/kg/day divided BID/TID — inhibits insulin release (K-ATP channel opener); side effects: edema, hirsutism, hyperuricemia

— Octreotide for tumors expressing SSTR2 receptors

— Everolimus or chemotherapy (streptozocin) for malignant insulinoma

— Reduce basal insulin by 10–20% after a severe nocturnal episode

— Switch glyburide → glipizide or DPP-4 inhibitor / GLP-1 RA / SGLT2 in elderly or CKD

— Discontinue sulfonylurea if eGFR <30 mL/min/1.73 m²

— Loosen A1c target (e.g., 7.5–8% in elderly, frail, limited life expectancy — per ADA/AGS)

— Initiate CGM for hypoglycemia unawareness or recurrent level-2 events

— Consider insulin pump or hybrid closed-loop in T1DM with recurrent severe hypoglycemia

— Strict avoidance of hypoglycemia for 2–3 weeks can restore counter-regulatory awareness

Acute reversal agents:

Insulinoma — pre/peri-operative or unresectable:

Diabetes regimen adjustments after hypoglycemia (outpatient, Step 3 bread-and-butter):

Address hypoglycemia unawareness:

Step 3 management: at discharge after any severe hypoglycemia, prescribe a glucagon kit, educate household members, and arrange diabetes education referral — these are commonly tested "next best step" items.

Board pearl: glyburide in elderly patients is on the Beers Criteria list — deprescribe and substitute.

Procedures and Invasive Management

— Surgical resection is curative in ~90% — enucleation for small benign lesions, distal pancreatectomy or Whipple for larger/head-of-pancreas lesions

— Pre-op localization: CT/MRI + EUS; intraoperative ultrasound + palpation

— Pre-op medical management with diazoxide; perioperative dextrose infusion

— Monitor for postoperative hyperglycemia (transient) and pancreatic fistula

— First-line: dietary — low-glycemic, small frequent meals, separate liquids from solids, avoid simple sugars

— Add acarbose (α-glucosidase inhibitor) to blunt postprandial glucose spikes

— Refractory: diazoxide, octreotide, GLP-1 receptor antagonists (investigational), surgical revision (reversal, pouch restriction) as last resort

— Indicated for T1DM, insulin-treated T2DM with recurrent hypoglycemia or unawareness

— Reduces severe hypoglycemia in randomized trials; Medicare covers for insulin users

— Consider for T1DM with severe recurrent hypoglycemia despite MDI optimization

— Automated insulin suspension during predicted hypoglycemia (low-glucose suspend) reduces nocturnal events

— Highly selected T1DM with severe unawareness refractory to all therapy

— Trade-off: lifelong immunosuppression

Insulinoma — definitive treatment:

Malignant insulinoma (~10%): debulking, liver-directed therapy (TACE, radiofrequency ablation), peptide receptor radionuclide therapy (177Lu-DOTATATE), everolimus

Post-bariatric (Roux-en-Y) hypoglycemia:

Continuous glucose monitor (CGM) — covered procedure-like intervention:

Insulin pump / hybrid closed-loop:

Pancreas or islet cell transplant:

CCS pearl: for a CCS case of suspected insulinoma — after biochemical confirmation, the orders flow is: pancreatic protocol CT → EUS if CT negative → surgical consult → diazoxide bridge → resection. Don't go to surgery before localization.

Board pearl: the most common cause of hypoglycemia after Roux-en-Y bypass is nesidioblastosis / noninsulinoma pancreatogenous hypoglycemia syndrome — present years after surgery, not days.

Special Populations — Elderly and Renal/Hepatic Impairment

— Decreased counter-regulatory response, polypharmacy, cognitive impairment, irregular meals

— Hypoglycemia → falls, fractures, MI, arrhythmia, dementia progression, mortality

— A1c target loosened: 7.5–8.0% (healthy elderly), 8.0–8.5% (frail, multiple comorbidities) per ADA/AGS

— Avoid glyburide, chlorpropamide (Beers Criteria); prefer metformin (if eGFR allows), DPP-4 inhibitors, GLP-1 RA

— Avoid tight basal-bolus insulin in cognitively impaired patients without caregiver support

— Insulin clearance is renal — basal/bolus doses fall as kidney function declines; reduce by 25–50% when eGFR <30

— Sulfonylureas accumulate in CKD — glyburide contraindicated below eGFR 60; glipizide preferred (hepatic metabolism) but still cautious

— Metformin: dose-reduce at eGFR 30–45, stop at eGFR <30 (lactic acidosis)

— Hypoglycemia is common in dialysis patients due to uremia, malnutrition, reduced gluconeogenesis

— Hemodialysis: glucose-containing dialysate to prevent intradialytic hypoglycemia

— Impaired gluconeogenesis and glycogenolysis → fasting hypoglycemia

— Glucagon ineffective (no hepatic glycogen) — must use IV dextrose

— Reduce sulfonylurea, repaglinide doses (hepatic metabolism)

— Hypoglycemia is a marker of severity and independent predictor of mortality

— ICU target: glucose 140–180 mg/dL (NICE-SUGAR), avoid tight control

Elderly diabetics — high-risk profile:

CKD (eGFR <60) and ESRD:

Hepatic failure:

Sepsis / critical illness:

Step 3 management: in a hospitalized elderly diabetic on glyburide with new AKI, hold the sulfonylurea immediately and switch to short-acting insulin sliding scale with frequent BG checks — failure to do so is the most common iatrogenic cause of inpatient hypoglycemia tested on exams.

Board pearl: "Hypoglycemia in an elderly diabetic admitted for pneumonia" — first stop the glyburide, second check renal function, third reduce basal insulin.

Special Populations — Pregnancy and Pediatrics

— Pregnant T1DM: increased hypoglycemia risk in first trimester (tight targets, nausea/vomiting, fetal glucose siphon)

— Targets: fasting <95, 1-h PP <140, 2-h PP <120 mg/dL — but avoid hypoglycemia <70

— Insulin requirements drop in T1, rise sharply in T2/T3, fall postpartum/lactation

— Preferred therapy: insulin (lispro, aspart, NPH, detemir); glyburide and metformin cross placenta and are no longer first-line per ADA

— Glucagon safe in pregnancy

— Threshold: <40 mg/dL in first 24 h, <45 mg/dL after 24 h (AAP guidance varies)

— Risk groups: infant of diabetic mother (IDM), LGA, SGA/IUGR, preterm, perinatal stress, sepsis

— IDM: transient hyperinsulinism from intrauterine hyperglycemia exposure

— Treatment: early feeding, dextrose gel buccal, IV D10W if persistent or symptomatic

— Persistent/severe: workup for congenital hyperinsulinism (K-ATP channel mutations) — diazoxide first-line, pancreatectomy if focal

— Ketotic hypoglycemia (most common in toddlers, fasting-related, self-resolves)

— Inborn errors: glycogen storage disease (type I — von Gierke), fatty acid oxidation defects (MCAD — hypoketotic hypoglycemia + hepatomegaly), galactosemia, hereditary fructose intolerance

— Hormonal: GH deficiency, congenital adrenal hyperplasia, hypopituitarism

— Salicylate or β-blocker ingestion

Pregnancy:

Gestational diabetes: rarely causes hypoglycemia unless on insulin

Neonatal hypoglycemia:

Pediatric hypoglycemia differential:

Workup principle: in pediatrics, always draw the "critical sample" during hypoglycemia — glucose, insulin, C-peptide, β-OHB, free fatty acids, lactate, ammonia, cortisol, GH, acylcarnitine profile, urine organic acids

Key distinction: hypoketotic hypoglycemia in a child = fatty acid oxidation disorder (MCAD) until proven otherwise; ketotic hypoglycemia with low insulin = benign ketotic hypoglycemia or hormonal deficiency.

Board pearl: an infant of a diabetic mother who becomes hypoglycemic at 2 hours of life — early feeding is the first intervention, IV dextrose if symptomatic or persistent <40.

Complications and Adverse Outcomes

— Seizure, coma, focal deficits (hypoglycemic hemiparesis), permanent cognitive impairment if prolonged (>4–6 h of glucose <40)

— Bilateral hippocampal and cortical injury on MRI in severe cases

— QT prolongation, ventricular arrhythmias, atrial fibrillation

— "Dead-in-bed syndrome" — sudden nocturnal death in young T1DM patients, attributed to hypoglycemia-induced arrhythmia

— Myocardial ischemia (catecholamine surge + ↑demand)

— In ACCORD trial, intensive glycemic control with frequent hypoglycemia → increased mortality

— Falls and fractures (elderly)

— Motor vehicle crashes — major medicolegal issue

— Burns, drownings during impaired episodes

— Hypoglycemia unawareness — blunting of autonomic warning

— Hypoglycemia-associated autonomic failure (HAAF) — impaired epinephrine and glucagon counter-regulation

— Both reversible with 2–3 weeks of strict hypoglycemia avoidance

— Fear of hypoglycemia → intentional hyperglycemia, worsening A1c

— Anxiety, depression, reduced quality of life

— Family/caregiver burnout

— In-hospital hypoglycemia is a patient safety indicator tracked by CMS

— Sliding-scale insulin alone, insulin held for NPO without basal adjustment, mistimed insulin–meal pairing are top inpatient causes

— Severe hypoglycemia is an independent predictor of mortality in both T1DM and T2DM, beyond what is explained by comorbidities

Acute neurologic:

Cardiovascular:

Trauma and accidents:

Recurrent hypoglycemia consequences:

Psychosocial:

Iatrogenic and systems-level:

Mortality:

Step 3 management: after a severe episode, document a hypoglycemia action plan in the discharge summary — household glucagon, CGM consideration, follow-up within 1–2 weeks. This closes the transitions-of-care loop tested on Step 3.

Board pearl: ACCORD showed that aggressive A1c targets (<6%) in high-risk T2DM increase mortality — the harm is mediated by hypoglycemia.

When to Escalate Care — ICU, Consult, Inpatient Triage

— Refractory hypoglycemia requiring continuous D10W or D20W infusion

— Sulfonylurea overdose with recurrent episodes

— Coma, seizure, or persistent altered mental status post-correction

— Concomitant hemodynamic instability, sepsis, or DKA-like illness

— Massive insulin ingestion (suicidal)

— Sulfonylurea ingestion — minimum 24 h observation (glyburide can recur at 18–24 h)

— Long-acting insulin (glargine, degludec) — observe 24 h minimum

— Hepatic or renal failure with hypoglycemia

— Hypoglycemia unawareness + severe episode

— Social concerns (homeless, food insecurity, abuse suspected)

— Endocrinology: unexplained nondiabetic hypoglycemia, suspected insulinoma, hypopituitarism, recurrent severe events

— Toxicology / Poison Control: suspected ingestion, sulfonylurea overdose, factitious

— Psychiatry: suicidal ingestion, factitious disorder, eating disorder

— Social work / Child Protective Services / Adult Protective Services: suspected malicious administration or factitious by proxy

— Surgery: insulinoma resection planning

— Diabetes educator and dietitian: all severe hypoglycemia at discharge

— Reversible cause, sustained euglycemia ≥4 h, eaten a meal

— Short-acting insulin / glipizide (not glyburide)

— Reliable home support, glucagon kit, follow-up arranged within 1–2 weeks

— Sulfonylurea-induced hypoglycemia (admit)

— Long-acting insulin overdose (admit)

— Suicidal intent (psych admit)

— Suspected child/elder abuse (involve protective services)

ICU admission criteria:

Step-down/floor admission:

Consults:

ED discharge — safe to send home only if:

Never discharge from ED:

CCS pearl: in a CCS case of glyburide-induced hypoglycemia, the correct disposition is admit, telemetry, D10W infusion, octreotide 50 mcg SC q6h, q1h fingersticks ×24 h — discharging from ED is the trap option.

Key Differentials — Same-Category (Endocrine/Metabolic) Causes

— ↑Insulin, ↑C-peptide, ↑proinsulin, ↓β-OHB, sulfonylurea screen negative

— 90% benign, solitary, pancreatic; consider MEN1 in young patients with multiple tumors

— Biochemistry mimics insulinoma but sulfonylurea screen positive

— Healthcare workers, family of diabetics, factitious disorder

— ↑Insulin, ↓C-peptide, ↓proinsulin

— Primary (Addison): low cortisol, high ACTH, hyperpigmentation, hyperkalemia, hyponatremia

— Secondary: low cortisol, low ACTH; no hyperkalemia (aldosterone intact); often part of hypopituitarism

— Diagnose with morning cortisol + cosyntropin stim

— GH and ACTH deficiency → fasting hypoglycemia

— Pituitary mass, Sheehan syndrome (postpartum), traumatic brain injury, autoimmune hypophysitis

— Large mesenchymal or epithelial tumors secreting big IGF-2

— ↑IGF-2:IGF-1 ratio, suppressed insulin/C-peptide

— Treat the tumor; bridge with glucocorticoids or GH

— Anti-insulin antibodies — episodic post-prandial hypoglycemia from delayed insulin release

— Associated with sulfhydryl-containing drugs (methimazole, captopril, α-lipoic acid) and Asian ancestry (HLA-DR4)

— Late postprandial pattern; positive mixed-meal test; diffuse β-cell hyperplasia

Insulinoma:

Factitious / accidental sulfonylurea or meglitinide:

Factitious exogenous insulin:

Adrenal insufficiency:

Hypopituitarism:

Glucagon deficiency: rare; usually from total pancreatectomy or long-standing T1DM (counter-regulatory failure)

Non-islet cell tumor hypoglycemia (NICTH):

Autoimmune insulin syndrome (Hirata disease):

Post-bariatric / nesidioblastosis:

Key distinction: the entire endocrine differential hinges on C-peptide + sulfonylurea screen + β-OHB drawn at the moment of hypoglycemia — without these, you cannot distinguish insulinoma from sulfonylurea from exogenous insulin.

Board pearl: big IGF-2:IGF-1 ratio with a large retroperitoneal mass = non-islet cell tumor hypoglycemia (often solitary fibrous tumor or hepatocellular carcinoma).

Key Differentials — Other-Category Causes

— Alcohol — inhibits gluconeogenesis; classic binge + poor intake → fasting hypoglycemia; thiamine before glucose in malnourished alcoholics to prevent Wernicke

— Quinolones (gatifloxacin > levofloxacin, moxifloxacin)

— Pentamidine — direct β-cell toxicity → initial hypoglycemia, later hyperglycemia

— Quinine, quinidine (malaria treatment)

— β-blockers — mask symptoms more than cause hypoglycemia; non-selective worst

— ACE inhibitors — potentiate insulin effect

— Tramadol, salicylates (children), haloperidol

— Inadvertent insulin/sulfonylurea dispensing errors (look-alike packaging)

— Sepsis — cytokine-mediated, multifactorial; harbinger of poor prognosis

— Hepatic failure — impaired gluconeogenesis

— Renal failure — reduced insulin clearance, reduced renal gluconeogenesis

— Cardiac failure — congestive hepatopathy, anorexia

— Anorexia nervosa, prolonged fasting, malabsorption, kwashiorkor/marasmus

— MCAD deficiency — hypoketotic hypoglycemia with fasting

— Glycogen storage disease type I (von Gierke) — hepatomegaly, hypoglycemia, lactic acidosis, hyperuricemia

— Galactosemia, hereditary fructose intolerance (food-triggered)

— Idiopathic, post-bariatric, early T2DM (delayed insulin peak)

— Consider in healthcare workers, parents of pediatric patients (Munchausen by proxy), spouses of diabetics

— Reportable to protective services if intentional harm suspected

Drug-induced (very high yield):

Critical illness:

Nutritional / starvation:

Inborn errors (pediatric, but tested):

Postprandial/reactive (functional):

Munchausen / factitious / malicious:

Key distinction: alcoholic hypoglycemia presents with ↓insulin, ↓C-peptide, ↑β-OHB, and importantly normal cortisol response — distinguishes from adrenal insufficiency.

Board pearl: the malnourished alcoholic with hypoglycemia gets thiamine 100 mg IV THEN D50 — order matters on exams.

Secondary Prevention and Long-Term Plan

— Match A1c target to patient: <7% (most adults), <7.5% (younger T1DM), 7.5–8% (older or comorbid), <8.5% (very frail, limited life expectancy)

— Substitute high-risk agents:

— Glyburide → glipizide, DPP-4i, GLP-1 RA, SGLT2i (note SGLT2i do not cause hypoglycemia as monotherapy)

— High-dose basal insulin → split dose, switch to degludec or glargine U-300 (lower nocturnal hypoglycemia vs NPH or U-100 glargine)

— Reduce basal insulin by 10–20% after a documented event

— Pre-meal insulin: dose with carb counting, give 15 min before meals

— CGM for T1DM and insulin-using T2DM — ADA Standard of Care; reduces severe hypoglycemia

— Hybrid closed-loop pumps for T1DM with recurrent severe events

— Predictive low-glucose suspend reduces nocturnal hypoglycemia by ~50%

— Symptom recognition, 15-15 rule

— Glucagon prescription — kit or intranasal Baqsimi; teach household

— Driving safety: check BG before driving; do not drive if <90; carry fast carbs

— Exercise: check BG pre/post; reduce pre-exercise insulin; bedtime snack after evening exercise

— Alcohol: pair with food, monitor BG, increased risk of nocturnal hypoglycemia

— Sick-day rules: continue basal insulin, check BG and ketones q4h, hydration

— Strict avoidance of glucose <70 for 2–3 weeks can restore awareness

— Loosen targets temporarily; use CGM alerts at 80

— Insulinoma: surgical resection is curative

— Post-bariatric: dietary low-glycemic + acarbose; surgical revision rarely

— Adrenal insufficiency: lifelong hydrocortisone, stress-dosing education, MedicAlert bracelet

Diabetes regimen redesign (post-hypoglycemia outpatient):

Technology:

Patient and family education:

Address hypoglycemia unawareness:

Nondiabetic causes:

Step 3 management: at discharge, prescribe glucagon, document A1c target, schedule follow-up at 1–2 weeks, and refer to certified diabetes care and education specialist — these are testable transition-of-care orders.

Board pearl: SGLT2 inhibitors and GLP-1 receptor agonists rarely cause hypoglycemia and are preferred add-ons in patients with prior severe events.

Follow-Up, Monitoring, and Counseling

— 1–2 weeks: PCP or endocrinology — review CGM/logbook, adjust regimen, reinforce education

— 3 months: HbA1c, reassess targets, glycemic variability

— 6–12 months: comprehensive diabetes care (foot exam, dilated eye exam, urine albumin-creatinine ratio, lipid panel)

— Self-monitoring BG ≥4×/day for insulin users, or CGM with time-in-range >70% (70–180 mg/dL) and time-below-range <4% (<70) and <1% (<54) — ADA targets

— HbA1c every 3 months until at target, then every 6 months

— Annual screening for hypoglycemia unawareness (Clarke/Gold scores)

— Severe hypoglycemia with LOC may require physician reporting in some states

— Patient self-restriction: check BG before driving, every 1–2 h on long drives, treat any reading <70 before driving, carry glucose

— Insulin-treated commercial drivers (DOT) need annual certification; severe hypoglycemia disqualifies until stable

— Carbohydrate counting and consistent meal timing

— Exercise planning with pre/post BG checks

— Alcohol moderation, food pairing

— Travel: time-zone insulin adjustments, carry extra supplies, letter for security

— Diabetes distress, fear of hypoglycemia, depression — screen with PHQ-9 annually

— Recognizing severe hypoglycemia, administering glucagon, when to call EMS

— Falls assessment in elderly

— Cognitive screening (MoCA) if prolonged neuroglycopenia

— Cardiac evaluation if arrhythmia documented

Post-hypoglycemia follow-up cadence:

Monitoring parameters:

Driving counseling (DMV implications):

Lifestyle counseling:

Mental health screening:

Family/caregiver education:

Rehabilitation after severe event:

Step 3 management: at the 1-week follow-up, review the CGM download or BG log line by line with the patient — pattern recognition (e.g., 3 AM dips → reduce basal; pre-dinner lows → reduce lunch bolus) is the highest-yield intervention.

Board pearl: time-in-range ≥70% correlates with HbA1c ~7% and is now a co-primary target alongside A1c.

Ethical, Legal, and Patient Safety Considerations

— Hospital hypoglycemia (BG <70) is a CMS-tracked quality measure and a never-event when severe and iatrogenic

— Top preventable causes: sliding-scale-only insulin, insulin given without meal, insulin not held for NPO/procedures, prescribing error (U-500 vs U-100 confusion), look-alike packaging

— Mitigations: standardized hypoglycemia protocols, double-check insulin doses, basal-bolus regimens over sliding scale, clear NPO–insulin communication at handoff

— Discharge medication reconciliation must explicitly address insulin and sulfonylurea

— Communicate dose changes to outpatient provider in discharge summary

— 7–14 day follow-up to catch over- or under-dosing

— Glucagon prescription and education before discharge

— Intensive insulin therapy — discuss hypoglycemia risk, especially in elderly

— CGM and pump initiation — discuss benefits, alarms, alarm fatigue

— Suspected malicious insulin administration (factitious by proxy in a child or impaired adult) → mandatory report to CPS/APS

— Healthcare worker with factitious hypoglycemia → report to occupational health and licensing board if patient access to insulin

— Some states mandate physician reporting of severe hypoglycemia with LOC

— Commercial drivers, pilots, machinery operators — counsel about glycemic targets and reporting requirements; document in chart

— Confront sensitively, involve psychiatry, do not abandon care; consider chain-of-custody for biochemistry

— In hospice/palliative patients, deintensify diabetes regimen — stop sulfonylureas, minimize insulin, accept hyperglycemia to avoid distressing hypoglycemia

Patient safety — inpatient hypoglycemia:

Transitions of care (Step 3 favorite):

Informed consent:

Mandatory reporting / protective services:

Driving and occupational safety:

Factitious disorder management:

End-of-life care:

Step 3 management: when a child presents with recurrent unexplained hypoglycemia and a parent who is a nurse, draw insulin/C-peptide during an episode and involve CPS — exogenous insulin (low C-peptide) confirms factitious by proxy and is mandatory to report.

Board pearl: in a frail nursing-home patient with A1c 6.2% on insulin, the safest "next step" is to deprescribe, not intensify — overtreatment is a documented quality-of-care failure.

High-Yield Associations and Rapid-Fire Clinical Facts

Insulinoma + MEN1 = pituitary adenoma + parathyroid hyperplasia + pancreatic NET (3 P's)

Sulfonylurea poisoning antidote = octreotide (suppresses insulin release)

β-blocker on hypoglycemic patient = blunts tachycardia but diaphoresis preserved

Alcoholic hypoglycemia = inhibited gluconeogenesis; give thiamine before dextrose

Whipple triad = symptoms + low glucose + relief with glucose; required to diagnose nondiabetic hypoglycemia

15-15 rule = 15 g carbs, recheck in 15 min, repeat ×3 max

C-peptide low + insulin high = exogenous insulin (factitious)

C-peptide high + sulfonylurea screen positive = sulfonylurea ingestion (often factitious)

C-peptide high + sulfonylurea screen negative = insulinoma

Big IGF-2 / IGF-2:IGF-1 ratio >10 = non-islet cell tumor hypoglycemia

Hypoketotic hypoglycemia in a child = MCAD deficiency

Hepatomegaly + hypoglycemia + lactic acidosis + hyperuricemia = von Gierke (GSD I)

Postprandial hypoglycemia years after Roux-en-Y = nesidioblastosis / noninsulinoma pancreatogenous hypoglycemia

Anti-insulin antibodies + Asian ancestry + methimazole exposure = Hirata disease (autoimmune insulin syndrome)

Pentamidine = initial hypoglycemia (β-cell lysis), late hyperglycemia

Quinine (malaria treatment) = hypoglycemia in severe falciparum

Glargine U-300 / degludec = lowest nocturnal hypoglycemia risk among basal insulins

CGM time-below-range target = <4% <70 mg/dL, <1% <54 mg/dL

ACCORD trial = intensive A1c <6% → ↑mortality via hypoglycemia in high-risk T2DM

Dead-in-bed syndrome = nocturnal hypoglycemia + arrhythmia in young T1DM

Hypoglycemia unawareness reversal = 2–3 weeks of strict glucose >70 avoidance

Beers Criteria = avoid glyburide in elderly

Hypoglycemia in CKD = stop glyburide, reduce insulin, stop metformin <eGFR 30

Glucagon failure = alcohol, malnutrition, prolonged fast, hepatic failure (no glycogen)

Board pearl: if the stem mentions a healthcare worker with episodic hypoglycemia, the answer is almost always factitious insulin administration — confirm with low C-peptide.

Board Question Stem Patterns

— Nurse with recurrent neuroglycopenia, normal between episodes

— Labs during episode: ↑insulin, ↓C-peptide, ↓proinsulin

— Answer: factitious exogenous insulin; involve psychiatry, occupational health

— AKI from sepsis → glyburide accumulation

— Answer: D50 push → D10W infusion + octreotide; admit ≥24 h; switch glyburide to glipizide or DPP-4i at discharge

— Whipple triad, fasting pattern

— 72-h fast: ↑insulin, ↑C-peptide, sulfonylurea screen negative

— Answer: insulinoma → pancreatic CT/MRI/EUS → surgical resection; screen for MEN1

— Answer: post-bariatric (nesidioblastosis) hypoglycemia; dietary modification + acarbose

— Answer: thiamine 100 mg IV → D50; glucagon would fail (no glycogen)

— Answer: MCAD deficiency; avoid fasting; emergency dextrose protocol

— Answer: reduce insulin doses (first trimester effect), avoid <70 targets, frequent small meals

— Answer: loosen A1c target, deprescribe sulfonylurea, switch to GLP-1 RA or DPP-4i

— Answer: systems issue — insulin not adjusted for NPO; root cause analysis; protocol-based insulin management

— Answer: NICTH (IGF-2); treat the tumor; bridge with glucocorticoids

Stem 1 — "Healthcare worker with episodic confusion":

Stem 2 — "Elderly diabetic on glyburide admitted with pneumonia, found unresponsive":

Stem 3 — "Young patient with episodic confusion relieved by eating, weight gain":

Stem 4 — "Patient 2 years post Roux-en-Y, postprandial palpitations and confusion":

Stem 5 — "Malnourished alcoholic found unresponsive, BG 38":

Stem 6 — "Toddler with morning lethargy, hepatomegaly, hypoketotic hypoglycemia":

Stem 7 — "Pregnant T1DM at 10 weeks with recurrent hypoglycemia":

Stem 8 — "T2DM in ACCORD-like scenario with A1c 6.2% and recurrent hypoglycemia":

Stem 9 — "Hospitalized patient on insulin drip becomes hypoglycemic after NPO order":

Stem 10 — "Large retroperitoneal mass + fasting hypoglycemia":

Step 3 management: the recurring "next best step" answers are: fingerstick first, draw paired insulin/C-peptide during hypoglycemia, octreotide for sulfonylurea, thiamine before dextrose in alcoholics.

One-Line Recap

Hypoglycemia is symptoms + low plasma glucose + relief with glucose (Whipple triad); treat acutely with oral carbs or IV dextrose, document the cause with paired insulin/C-peptide/β-OHB/sulfonylurea screen drawn during the episode, and prevent recurrence by deprescribing high-risk agents (glyburide in elderly/CKD), individualizing A1c targets, prescribing glucagon, and using CGM in insulin-treated patients.

Diagnostic backbone: Whipple triad + critical sample (glucose, insulin, C-peptide, proinsulin, β-OHB, sulfonylurea screen, cortisol) drawn while hypoglycemic — without it, the workup is uninterpretable.

Acute treatment ladder: 15-15 oral carbs → D50 IV (or glucagon IM if no access) → D10W infusion + octreotide for sulfonylurea → hydrocortisone if adrenal insufficiency suspected → thiamine before dextrose in malnourished alcoholics.

Differential by C-peptide: high C-peptide + negative sulfonylurea = insulinoma; high C-peptide + positive sulfonylurea = ingestion; low C-peptide + high insulin = exogenous insulin; low both + high β-OHB = alcohol, AI, hypopituitarism, sepsis, hepatic failure; low both + suppressed β-OHB + ↑IGF-2 = non-islet cell tumor.

Step 3 transitions: at discharge after severe hypoglycemia, prescribe glucagon, educate the household, loosen A1c if appropriate, substitute or stop glyburide, arrange 1–2 week follow-up, and refer to diabetes education — these closing orders are the most commonly tested management endpoints.